Golding J F, Gosden E, Gerrell J
Institute of Naval Medicine, Gosport, Hants, United Kingdom.
Aviat Space Environ Med. 1991 Jun;62(6):521-6.
Speed of absorption and elimination of an antimotion sickness drug sets limits on the protection afforded. The aim of this experiment was to determine whether a well proven antimotion sickness drug--scopolamine (hyoscine)--could be absorbed more rapidly from buccal tablets than from the standard issue ingested tablets. Plasma scopolamine levels were measured using a radioreceptor assay of repeated blood samples from 10 volunteers, each of whom took buccal and standard ingested tablets (both 0.6 mg scopolamine hydrobromide) on two different occasions, and from a further 8 volunteers following ingestion of a pharmacy-prepared scopolamine capsule (0.6 mg scopolamine hydrobromide). There was no statistically significant speed advantage for the buccal tablet (mean time to peak levels approx 50 min). Individual variation in the speed of scopolamine absorption and rate of elimination (mean half-life approx 170 min) was great. This may account for failure of motion sickness protection in some individuals.
抗晕动病药物的吸收和消除速度对其所提供的保护作用设定了限制。本实验的目的是确定一种久经验证的抗晕动病药物——东莨菪碱（天仙子碱）——从口腔含片吸收的速度是否比从标准口服片剂吸收得更快。使用放射受体分析法对10名志愿者重复采集的血样中的血浆东莨菪碱水平进行测量，每位志愿者在两个不同的时间分别服用口腔含片和标准口服片剂（均为0.6毫克氢溴酸东莨菪碱），另外8名志愿者在服用药房配制的东莨菪碱胶囊（0.6毫克氢溴酸东莨菪碱）后也进行了测量。口腔含片在吸收速度上没有统计学上的显著优势（达到峰值水平的平均时间约为50分钟）。东莨菪碱吸收速度和消除速率（平均半衰期约为170分钟）的个体差异很大。这可能是导致某些个体晕动病防护失败的原因。
